References
- 1. Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7(10):5217-36. DOI: 10.1002/cam4.1501
- 2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907. DOI: 10.1016/S0140-6736(07)61416-0
- 3. Lang-Schwarz C, Melcher B, Haumaier F, Lang-Schwarz K, Rupprecht T, Vieth M, et al. Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups. Hum Pathol. 2018;79:160-7. DOI: 10.1016/j.humpath.2018.05.01029787819
- 4. Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015;4(9):e985930. DOI: 10.4161/2162402X.2014.985930457011226405612
- 5. Ikeda Y, Kiyotani K, Yew PY, Sato S, Imai Y, Yamaguchi R, et al. Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer. Oncol Rep. 2017;37(5):2603-10. DOI: 10.3892/or.2017.5536542828528358435
- 6. Ohno A, Iwata T, Katoh Y, Taniguchi S, Tanaka K, Nishio H, et al. Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy. Gynecol Oncol. 2020;159(2):329-34. DOI: 10.1016/j.ygy-no.2020.07.106
- 7. Wu MY, Kuo TY, Ho HN. Tumor-infiltrating lymphocytes contain a higher proportion of FOXP3(+) T lymphocytes in cervical cancer. J Formos Med Assoc. 2011;110(9):580-6. DOI: 10.1016/j.jfma.2011.07.00521930068
- 8. Cochain C, Vafadarnejad E, Arampatzi P, Pelisek J, Winkels H, Ley K, et al. Single-Cell RNA-Seq Reveals the Transcriptional Landscape and Heterogeneity of Aortic Macrophages in Murine Atherosclerosis. Circ Res. 2018;122(12):1661-74. DOI: 10.1161/CIRCRESAHA.117.31250929545365
- 9. Xu C, Sun L, Jiang C, Zhou H, Gu L, Liu Y, et al. SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway. Biomed Pharmacother. 2017;91:1167-77. DOI: 10.1016/j.biopha.2017.05.05628531945
- 10. Hao C, Cui Y, Hu MU, Zhi X, Zhang L, Li W, et al. OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro. Anticancer Res. 2017;37(5):2245-54. DOI: 10.21873/anticanres.1156128476789
- 11. Zeng B, Zhou M, Wu H, Xiong Z. SPP1 promotes ovarian cancer progression via Integrin beta1/FAK/AKT signaling pathway. Onco Targets Ther. 2018;11:1333-43. DOI: 10.2147/OTT.S154215585606329559792
- 12. Gothlin Eremo A, Lagergren K, Othman L, Montgomery S, Andersson G, Tina E. Evaluation of SPP1/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer. Sci Rep. 2020;10(1):1451. DOI: 10.1038/s41598-020-58323-w698962931996744
- 13. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509-W14. DOI: 10.1093/nar/gkaa407731957532442275
- 14. Chen Z, Guo P, Xie X, Yu H, Wang Y, Chen G. The role of tumour microenvironment: a new vision for cholangiocarcinoma. J Cell Mol Med. 2019;23(1):59-69. DOI: 10.1111/jcmm.13953630784430394682
- 15. Su J, Su L, Li D, Shuai O, Zhang Y, Liang H, et al. Antitumor Activity of Extract From the Sporoderm-Breaking Spore of Ganoderma lucidum: Restoration on Exhausted Cytotoxic T Cell With Gut Microbiota Remodeling. Front Immunol. 2018;9:1765. DOI: 10.3389/fimmu.2018.01765607921730108589
- 16. Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020;20(5):294-307. DOI: 10.1038/s41577-019-0257-x31988391
- 17. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42(6):717-27. DOI: 10.1016/j.ejca.2006.01.00316520032
- 18. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66(11):5527-36. DOI: 10.1158/0008-5472.CAN-05-412816740684
- 19. Ustyanovska Avtenyuk N, Visser N, Bremer E, Wiersma VR. The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. Int J Mol Sci. 2020;21(21):7820. DOI: 10.3390/ijms21217820765993733105656
- 20. Kong W, Zhao G, Chen H, Wang W, Shang X, Sun Q, et al. Analysis of therapeutic targets and prognostic biomarkers of CXC chemokines in cervical cancer microenvironment. Cancer Cell Int. 2021;21(1):399. DOI: 10.1186/s12935-021-02101-9831741534321012